References used in PEPlife

This page gives the users the articles related to half-life of peptides and their link on Pubmed.
Title PMID
A novel stearic acid-modified hirudin peptidomimetic with improved pharmacokinetic properties and anticoagulant activity. 26400022
A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis. 26337231
In vivo pharmacological evaluation of a lactose-conjugated luteinizing hormone releasing hormone analogue. 26325323
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. 26308095
Degradation and Stabilization of Peptide Hormones in Human Blood Specimens. 26222180
The anorexic hormone Peptide YY3-36 is rapidly metabolized to inactive Peptide YY3-34 in vivo. 26197931
Half-life extension of the HIV-fusion inhibitor peptide TRI-1144 using a novel linker technology. 25900863
A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer. 25894376
A recombinant slow-release PACAP-derived peptide alleviates diabetes by promoting both insulin secretion and actions. 25771000
Pharmacokinetics and pharmacodynamics of the glucagon-like peptide-1 analog liraglutide in healthy cats. 25625650
Glycosylated enfuvirtide: a long-lasting glycopeptide with potent anti-HIV activity. 25594223
Myristic acid conjugation of [D-Leu-4]-OB3, a biologically active leptin-related synthetic peptide amide, significantly improves its pharmacokinetic profile and efficacy. 25453979
Assessment of Pharmacokinetics and Toxicology of Sadat-Habdan Mesenchymal Stimulating Peptide (SHMSP) in Rats and Goats. 25324697
Long-acting GLP-1 analogue in V-shaped conformation by terminal polylysine modifications. 25243635
Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability. 25039358
A potent anti-thrombosis peptide (vasotab TY) from horsefly salivary glands. 25025626
Biological properties of adrenomedullin conjugated with polyethylene glycol. 24874704
Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs. 24588343
Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin. 24462899
Combination of hybrid peptide with biodegradable gelatin hydrogel for controlled release and enhancement of anti-tumor activity in vivo. 24378440
Pharmacokinetics of teriparatide after subcutaneous administration to volunteers with renal failure: a pilot study. 24361089
Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA). 24139844
Extension of in vivo half-life of biologically active peptides via chemical conjugation to XTEN protein polymer. 24133142
Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents. 23836030
First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. 23813302
Cytotoxicity and vitreous stability of chemically modified connexin43 mimetic peptides for the treatment of optic neuropathy. 23696181
Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. 23318685
The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs. 23318502
In vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery. 23196806
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers. 23099431
Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study. 22934681
Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation. 22770564
PEGylation of an osteoclast inhibitory peptide: suitable candidate for the treatment of osteoporosis. 22698865
The analysis of exogenous ghrelin plasma activity and tissue distribution. 22592200
A new strategy for metabolic stabilization of motilin using the C-terminal part of ghrelin. 22286034
Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: semisynthesis, in vitro activity and pharmacokinetics in rats. 22263969
Microbial degradation of physiologically active peptides by strain B-9. 22186872
Development and in vivo characterization of a novel peptide drug delivery system providing extended plasma half life. 21986100
An LC-MS/MS assay to determine plasma pharmacokinetics of cyclic thymic hexapeptide (cTP6) in rhesus monkeys. 21903490
A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo. 21664938
Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. 21459096
Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo. 21334413
Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss webster mice. 21329733
Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. 21244372
Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy. 21210710
Bactericidal oncocin derivatives with superior serum stabilities. 21185160
Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes. 21114599
Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. 21036718
Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. 20844765
Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges. 20687610
Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety. 20631047
Synthesis and characterization of ester-based prodrugs of glucagon-like peptide 1. 20593470
Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa. 20587645
Easy strategy to protect antimicrobial peptides from fast degradation in serum. 20585128
Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists. 20560643
Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. 20503261
Gcg-XTEN: an improved glucagon capable of preventing hypoglycemia without increasing baseline blood glucose. 20418955
Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. 20382695
A cell permeable peptide analog as a potential-specific PET imaging probe for prostate cancer detection. 20221650
Biodistribution and pharmacokinetics of PEG-10kDa-cholecystokinin-10 in rats after different routes of administration. 20158487
A sandwich ELISA for assessment of pharmacokinetics of HSA-(BNP)2 fusion protein in mouse plasma. 19836183
Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. 19805567
Differential elicitation of an aspartic protease inhibitor: regulation of endogenous protease and initial events in germination in seeds of Vigna radiata. 19770015
Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. 19767127
The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. 19762245
Design of proteolytically stable RI-anchoring disruptor peptidomimetics for in vivo studies of anchored type I protein kinase A-mediated signalling. 19715558
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. 19602537
TAT peptide and its conjugates: proteolytic stability. 19601640
Effect of PEGylation of N-WASP181-200 on the inhibitory potency for renal aminoglycoside accumulation. 19572636
Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. 19552923
Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies. 19533722
Poly-GLP-1, a novel long-lasting glucagon-like peptide-1 polymer, ameliorates hyperglycaemia by improving insulin sensitivity and increasing pancreatic beta-cell proliferation. 19531053
A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. 19458086
Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. 19422857
Studies of poly(ethylene glycol) modification of HM-3 polypeptides. 19413309
Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation. 19403044
Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. 19344673
Safety, pharmacokinetic and pharmacodynamic studies of batifiban injection following single- and multiple-dose administration to healthy Chinese subjects. 19224155
Identification and characterization of a peptide with affinity to head and neck cancer. 19223422
N-terminal pro-brain natriuretic peptide and atrial fibrillation. 19165353
Rapid profiling of peptide stability in proteolytic environments. 19159331
NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke. 19157421
The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo. 19115392
Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. 19053766
A combined in vitro and in vivo study on the interactions between somatostatin and lipid-based liquid crystalline drug carriers and bilayers. 19041716
Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization. 19023544
Degradation of salmon calcitonin in rat kidney and liver homogenates. 18972837
Carbofuran poisoning detected by mass spectrometry of butyrylcholinesterase adduct in human serum. 18937214
Estrogen elevates the peak overnight production rate of acylated ghrelin. 18697865
99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. 18632826
In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. 18602197
N-terminal pro B-type natriuretic peptide is an independent predictor of postoperative myocardial injury in patients undergoing major vascular surgery. 18586440
Evaluation of postmortem measurement of NT-proBNP as a marker for cardiac function. 18553094
Synthetic collagen heterotrimers: structural mimics of wild-type and mutant collagen type I. 18481852
N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. 18424366
Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. 18413862
Novel stable PACAP analogs with potent activity towards the PAC1 receptor. 18353507
Antimicrobial peptides with stability toward tryptic degradation. 18307313
Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer. 18249125
Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats. 18085721
Pharmacokinetics and pharmacology of hirulog-like peptide. 18049308
Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. 17994612
One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique. 17986790
Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation. 17904340
Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting. 17766836
Influence of chelate conjugation on a newly identified tumor-targeting peptide. 17704241
Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. 17684103
NC100668, a new tracer tested for imaging of venous thromboembolism: pharmacokinetics and metabolism in humans. 17682073
Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. 17640899
Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. 17583927
Bioactive analogues and drug delivery systems of vasoactive intestinal peptide (VIP) for the treatment of asthma/COPD. 17537541
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. 17532097
Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. 17498958
ANP is cleared much faster than BNP in patients with congestive heart failure. 17479256
Metabolism of cydiastatin 4 and analogues by enzymes associated with the midgut and haemolymph of Manduca sexta larvae. 17408666
Angiotensin converting enzyme inhibitory peptides from a lactotripeptide-enriched milk beverage are absorbed intact into the circulation. 17374660
Biological activity of AC3174, a peptide analog of exendin-4. 17292977
N-terminal pro-atrial natriuretic peptide and exercise prescription in patients with myocardial infarction. 17292492
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes. 17283237
Stability of synthetic exendin-4 in human plasma in vitro. 17266646
Biological half-life and organ distribution of [3H]8-arginine vasopressin following administration of vasopressin receptor antagonist OPC-31260. 17258819
Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. 17204551
Metabolism of glucagon-like peptide-2 in pigs: role of dipeptidyl peptidase IV. 17107718
Effects of peripheral administration of PYY3-36 on feed intake and plasma acyl-ghrelin levels in pigs. 17065394
cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo. 16990557
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. 16982323
Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. 16892368
Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice. 16828890
PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. 16586064
Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. 16476851
Molecular basis for phosphorylation-dependent, PEST-mediated protein turnover. 16472750
Glioma cell integrin expression and their interactions with integrin antagonists: Research Article. 16467916
Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. 16302271
Hemostatic effects of phospholipid vesicles carrying fibrinogen gamma chain dodecapeptide in vitro and in vivo. 16287259
Stability and degradation profiles of Spantide II in aqueous solutions. 16266798
Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. 16197609
Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. 16099941
A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. 16023182
Effect of urocortin 1 infusion in humans with stable congestive cardiac failure. 15882144
Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. 15828822
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. 15817669
Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. 15769092
Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin. 15740458
Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. 15656696
AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure. 15587934
The direct thrombin inhibitor melagatran/ximelagatran. 15487959
Half-life of leu-enkephalin in the serum of infants of the first year of life on different types of feeding: relationship with temperament. 15452596
Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. 15369394
Systemic catabolism of Alzheimer's Abeta40 and Abeta42. 15322125
Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. 15246869
N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. 15012592
Using spectrophotometry to determine in vitro turnover rates of peptides in plasma. 14980787
N-acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression. 14759771
Structure-based design of an indolicidin peptide analogue with increased protease stability. 14640680
PEGylation of growth hormone-releasing hormone (GRF) analogues. 14499707
In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues. 12954066
Haemodynamic action of B-type natriuretic peptide substantially outlasts its plasma half-life in conscious dogs. 12859428
Novel bioactive and stable neurotensin peptide analogues capable of delivering radiopharmaceuticals and molecular beacons to tumors. 12852770
Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo. 12699744
Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. 12578830
Utilization of a radioimmunoassay to detect the generation of Arg-Pro-Pro-Gly-Phe, a stable endproduct of bradykinin metabolism (from cultured rat aortic smooth muscle cells exposed to bradykinin). 12489813
In vitro human plasma leucine(5)-enkephalin degradation is inhibited by a select number of drugs with the phenothiazine molecule in their chemical structure. 12444298
Albumin affinity tags increase peptide half-life in vivo. 12270169
A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. 12220890
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. 12145241
Albumin binding as a general strategy for improving the pharmacokinetics of proteins. 12119302
Clinical pharmacokinetics of depot leuprorelin. 12083977
Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. 12047915
The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. 12039708
Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. 11976797
In vivo pharmacokinetics of calreticulin S-domain, an inhibitor of the classical complement pathway. 11962721
Biodistribution, blood half-life, and receptor binding of a somatostatin-dextran conjugate. 11778971
The amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture. 11553691
Binding protein-3-selective insulin-like growth factor I variants: engineering, biodistributions, and clearance. 11145579
A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. 11099487
Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase. 11054637
Catalytic life of activated factor XIII in thrombi. Implications for fibrinolytic resistance and thrombus aging. 10973845
Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. 10871321
Designing stable blood-brain barrier-permeable prosaptide peptides for treatment of central nervous system neurodegeneration. 10773009
Biodistribution of liposomal 131I-VIP in rat using gamma camera. 10708307
Human thyrotropin-releasing hormone-associated peptide 3 (hTAP-3) in serum. 10670753
Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. 10647619
Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. 10611139
Transport of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites in rats. 10607940
Pharmacokinetics and hematological effects of the PEGylated thrombopoietin peptide mimetic GW395058 in rats and monkeys after intravenous or subcutaneous administration. 10606160
Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. 10541299
The effect of halogenation on blood-brain barrier permeability of a novel peptide drug. 10573295
Bioconjugation of laminin-related peptide YIGSR with polyvinyl pyrrolidone increases its antimetastatic effect due to a longer plasma half-life. 10544005
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. 10495424
Design, synthesis and characterization of antimicrobial pseudopeptides corresponding to membrane-active peptide. 10461747
PGFM response to exogenous oxytocin and determination of the half-life of oxytocin in nonpregnant mares. 10454085
The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. 10377427
Thioamides: synthesis, stability, and immunological activities of thioanalogues of Imreg. Preparation of new thioacylating agents using fluorobenzimidazolone derivatives. 10354413
Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematol... 9932163
gamma-secretase cleavage is distinct from endoplasmic reticulum degradation of the transmembrane domain of the amyloid precursor protein. 9822665
Pharmacokinetics of the bicyclic peptide tachykinin NK2 receptor antagonist MEN 11420 (nepadutant) in rats. 9806949
Converting enzyme determines plasma clearance of angiotensin-(1-7). 9740616
Disposition of 14C-eptifibatide after intravenous administration to healthy men. 9589822
Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism. 9421401
Dynorphin A (1-8) analog, E-2078, is stable in human and rhesus monkey blood. 9067297
No. 302, a newly synthesized [pGlu4,Cyt6]AVP(4-9) analogue, prevents the disruption of avoidance behavior. 9062685
Radioimmunoassay of meterelin and pharmacokinetics after single injection and implant administration in dogs. 9040091
Processing of [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P in xenograft bearing Nu/Nu mice. 9357069
High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor. 8910426
Pharmacokinetics and toxicokinetics of an orally active tripeptide, IRI-695, in animals. 8991489
Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma. 8839678
Haemodynamic responses to rat adrenomedullin in anaesthetized spontaneously hypertensive rats. 8542672
Degradation of IGF-I in the adult rat gastrointestinal tract is limited by a specific antiserum or the dietary protein casein. 7561632
Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies. 8545255
In vitro stability of some reduced peptide bond pseudopeptide analogues of dynorphin A. 8545241
Nasal mucosal metabolism and absorption of pentapeptide enkephalin analogs having varying N-terminal amino acids. 7714746
Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. 7994807
The effect of cyclodextrins on the stability of peptides in nasal enzymic systems. 7899230
Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. 7962302
Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. 7529108
In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera. 9234336
Heterogeneity in hepatic transport of somatostatin analog octapeptides. 8020889
Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatography. 7522585
Prevention of diabetes by thymic hormone in alloxan-treated rats. 8082705
N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. 8181115
Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. 8076909
The role of the kidney in the clearance of calcitonin gene related peptide (CGRP). 8147781
Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. 8289671
Synthetic human adrenomedullin and adrenomedullin 15-52 have potent short-lived vasodilator activity in the hindlimb vascular bed of the cat. 8035644
Pharmacokinetics and organ distribution of the sorbin C-terminal peptides. 7991443
Growth hormone-releasing activity of hexarelin in humans. A dose-response study. 7957536
Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. 7911441
Distribution and metabolism patterns of plasma 7S- and beta-NGF in the adult male rat. 7787827
Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. 8257427
Biphasic effects of suramin on 125I-epidermal growth factor binding to human meningiomas. 8194082
Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. 8222093
Atrial natriuretic factor and transgenic mice. 8406670
Mass spectrometry and characterization of Aedes aegypti trypsin modulating oostatic factor (TMOF) and its analogs. 8353526
Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. 8353280
The intrarenal site of calcitonin gene-related peptide degradation in the isolated perfused rat kidney. 8403527
Functional peptide-polyurethane conjugates with extended circulatory half-lives. 8218482
On the effects of human galanin in man. 7689499
Degradation of bradykinin by neutral endopeptidase (EC in cultured human endothelial cells. 8395230
Effect of low dose infusions of ile-atrial natriuretic peptide in healthy elderly males: evidence for a postreceptor defect. 8388403
Desensitisation of the cardiac response to somatostatin in isolated toad atria but not in whole toads. 8100840
Optimization of cell culture conditions for the evaluation of the biological activities of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro, a natural hemoregulatory factor. 8217216
Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain. 1418002
A comparison of the clearance of ovine and human corticotrophin-releasing hormone (CRH) in man and sheep: a possible role for CRH-binding protein. 1319455
Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. 1551497
Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonists. 1329046
The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. 1730807
Pharmacokinetics and short-term metabolic effects of mammalian cell-derived biosynthetic human growth hormone in man. 1490668
Kinetics of atrial natriuretic peptide in young and elderly subjects. 1387608
Metabolic half-life of somatostatin and peptidase activities are altered in Alzheimer's disease. 1346149
Leucine aminopeptidase-like activity in Aplysia hemolymph rapidly degrades biologically active alpha-bag cell peptide fragments. 1939259
The potential for prazosin and calcitonin gene-related peptide (CGRP) in causing hypoxia in tumours. 1911217
Hypothalamic degradation of galanin(1-29) and galanin(1-16): identification and characterization of the peptidolytic products. 1723638
Effects of brain natriuretic peptide-45, a circulating form of rat brain natriuretic peptide, in spontaneously hypertensive rats. 1664804
Development of enzyme-linked immunosorbent assay for free human pro-colipase activation peptide (APGPR). 1777964
Oral sodium regulates extrahepatic metabolism of vasoactive intestinal peptide. 1649728
Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans. 1651738
Gonadotropin-releasing hormone (GnRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats. 1882091
Accelerated in vitro degradation of CCK-58 in blood and plasma of patients with acute pancreatitis. 1889124
Plasma clearance and tissue binding of rANP[99-126] and iso-rANP[1-45] in the rat. 1646465
Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizes. 1904406
Effects of atrial natriuretic peptide (99-126) in chronic renal disease in man. 1831249
In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma. 1826667
Increased microvascular permeability in vivo in response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. 1824807
Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS). 1763193
Glucagon-(19-29), a Ca2+ pump inhibitory peptide, is processed from glucagon in the rat liver plasma membrane by a thiol endopeptidase. 2147684
Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction. 2147696
In vivo metabolism of brain natriuretic peptide in the rat involves endopeptidase 24.11 and angiotensin converting enzyme. 2175178
Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat. 1697165
Peptide histidine valine: its haemodynamic actions and pharmacokinetics in man differ from those of vasoactive intestinal peptide and peptide histidine methionine. 2162275
Brain natriuretic peptide administered to man: actions and metabolism. 2156886
Tissue distribution and half-life of 125I-endothelin in the rat: importance of pulmonary clearance. 2182027
Extended presence of antide (Nal-Lys GnRH antagonist) in circulation: prolonged duration of gonadotropin inhibition may derive from antide binding to serum proteins. 2298867
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. 2687064
Transdermal peptide delivery. 2533571
Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis. 2498387
GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. 2714145
An in vitro system for study of effects of angiotensin I on cultured endothelial cells. 2556215
Simulation of the activation of fat body glycogen phosphorylase and trehalose synthesis by peptide hormones in the American cockroach. 2624887
Rectal absorption enhancement of des-enkephalin-gamma-endorphin (DE gamma E) by medium-chain glycerides and EDTA in conscious rats. 2524034
Pharmacokinetics of vasopressin and atrial natriuretic peptide in anesthetized rabbits. 2521208
Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. 3147901
Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. 2970910
Pharmacokinetics and organ-specific metabolism of calcitonin gene-related peptide in sheep. 3261772
Serum half-life and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins. 2454805
Plasma half-lives of native and modified insulin-like growth factor-I in lambs. 3379352
Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental metastasis of B16-F10 murine melanoma cells. 3343338
A preliminary study of the pharmacodynamics and pharmacokinetics of a novel enkephalin analogue [Tyr-D.Arg-Gly-Phe (4NO2).Pro.NH2 (BW443C)] in healthy volunteers. 3360050
Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. 3348603
Studies of the in vitro human plasma degradation of methionine-enkephalin. 3215483
NH2-terminal fragment of rat pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. 2966345
Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide. 2896343
Cardiac vagal action and plasma levels of neuropeptide Y following intravenous injection in the dog. 3601235
Pharmacokinetics of synthetic atrial natriuretic peptides in normal men. 2953516
Effects of insulin-like growth factor I (IGF-I) on growth hormone-releasing factor (GRF) and thyrotropin-releasing hormone (TRH) stimulation of growth hormone (GH) secretion in the domestic fowl (Gallus domesticus). 3108068
Kinetics of four 11C-labelled enkephalin peptides in the brain, pituitary and plasma of rhesus monkeys. 3492729
Plasma half-life of DDAVP in uraemic patients. 3799211
Direct radioimmunoassay for human atrial natriuretic peptide (hANP) and its clinical evaluation. 2945560
Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters. 3768731
Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. 2939312
Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. 2940625
Disappearance of atrial natriuretic factor from circulation in the rat. 2942845
In vivo interaction of synthetic acylated apopeptides with high density lipoproteins in rat. 3080478
Circulating somatostatin concentrations in healthy and cirrhotic subjects. 2868381
Growth hormone-releasing factor analogue (hGRF1-29NH2): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. 2866222
Synthesis and biological activity of pentapeptide analogues of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline. 2991517
Effects and pharmacokinetic properties of the rat/human corticotropin-releasing factor in rhesus monkeys. 2988919
Radioimmunoassay for human growth hormone-releasing factor (hGRF 1-40): comparison of plasma immunoreactive GRF after intravenous and subcutaneous administration to rats. 3924685
Des-Tyr1-gamma-endorphin (DT gamma E) and des-enkephalin-gamma-endorphin (DE gamma E): plasma profile and brain uptake after systemic administration in the rat. 4070016
Enkephalin pseudopeptides: resistance to in vitro proteolytic degradation afforded by amide bond replacements extends to remote sites. 4034413
Infusion of a novel peptide, calcitonin gene-related peptide (CGRP) in man. Pharmacokinetics and effects on gastric acid secretion and on gastrointestinal hormones. 3922013
Unglycosylated rat alpha 1-proteinase inhibitor has a six-fold shorter plasma half-life than the mature glycoprotein. 3871610
Distribution and metabolism of dermorphin in rats. 6522442
Serum concentration patterns of an LHRH agonist, gonadotrophins and sex steroids after subcutaneous, vaginal, rectal and nasal administration of the agonist to pregnant rats. 6433008
Depressor and natriuretic activities of several atrial peptides. 6239307
The hydra head activator in human blood circulation. Degradation of the synthetic peptide by plasma angiotensin-converting enzyme. 6086405
Gastrin-releasing peptide: pharmacokinetics and effects on gastro-entero-pancreatic hormones and gastric secretion in normal men. 6736205
Corticotropin-releasing factor: pharmacokinetics in man. 6605972
Endocrine responses to exogenous bombesin and gastrin releasing peptide in conscious calves. 6361234
Disposition of human fibrinopeptide A in normal and nephrectomized rabbits. 6658706
In vitro synthesis of the tryptophan operon leader peptides of Escherichia coli, Serratia marcescens, and Salmonella typhimurium. 6344071
The in vivo metabolism of somatostatin 28: possible relationship between diminished metabolism and enhanced biological action. 6127205
Comparison of the gastric exocrine inhibitory activities and plasma kinetics of somatostatin-28 and somatostatin-14 in cats. 6128770
Degradation of cholecystokinin octapeptide, related fragments and analogs by human and rat plasma in vitro. 6291099
H-Pro-[3H]Leu-Gly-NH2: plasma profile and brain uptake following subcutaneous injection in the rat. 6121002
Radioimmunoassay study of hepatic clearance and disappearance half-time of somatostatin and vasoactive intestinal peptide in dogs. 6117506
The level and half-life of glutathione in human plasma. 7439398
Long term stability of lysine vasopressin and of specifically tritiated lysine vasopressin in weakly acidic aqueous solutions. 7418787
Anticandidal activity of 5-fluorocytosine-peptide conjugates. 385880
Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. 730072
Kinetics of human connecting peptide in normal and diabetic subjects. 659633
Capitalism, costs, and the shape of service: reply to a critique. 641324
Immunological half-life of porcine proinsulin C-peptide. 1213660
The distribution, half-life, and excretion of tritiated luteinizing hormone-releasing hormone (LH-RH) in rats. 4572061
Lysistrata looks at another burden on health visitors. 5092290
Structure-activity relationships of synthetic adrenocorticotropic octadecapeptides with special reference to biological half-life. 4327730